Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2000
02/03/2000WO2000004886A1 Formulations for the transdermal administration of fenoldopam
02/03/2000WO2000004884A1 Pharmaceutical preparations for the topical treatment of mucocutaneous herpes infections and herpetic keratitis of the eye
02/03/2000WO2000004883A1 Diltiazem controlled release formulation and method of manufacture
02/03/2000WO2000004882A1 Formulations of anionic polysaccharides
02/03/2000WO2000004881A1 Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method
02/03/2000WO2000004880A1 A wet granulation method for preparing a stable pharmaceutical formulation
02/03/2000WO2000004879A1 Granule modulating hydrogel system
02/03/2000WO2000004878A1 Pharmaceutical composition in particular for preventing and treating mucositis induced by radiotherapy or chemotherapy
02/03/2000WO2000004877A1 Suppository formulations comprising anionic polysaccharide
02/03/2000WO2000004875A2 Preparation of aqueous clear solution dosage forms with bile acids
02/03/2000WO2000004870A2 Composition for enhancing epidermal lipid production
02/03/2000WO2000004868A2 Libraries of polyhydroxamates and their analogs
02/03/2000WO2000004866A2 Preparation of thioarabinofuranosyl compounds and use thereof
02/03/2000WO2000004865A2 Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
02/03/2000WO2000004862A2 Bioenhanced formulations comprising eprosartan in oral solid dosage form
02/03/2000WO1999066903A3 Large porous particles emitted from an inhaler
02/03/2000WO1999065922A3 Prenyl transferase inhibitors
02/03/2000WO1999064417A3 Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
02/03/2000WO1999064001A3 Methods and compositions for increasing penetration of hiv protease inhibitors
02/03/2000WO1999063942A3 Isolation and structural elucidation of the human cancer cell growth inhibitory compound denominated 'agelagalastatin'
02/03/2000WO1999063936A3 Novel therapeutic agents that modulate endothelin receptors
02/03/2000WO1999063933A3 Multivalent agonists, partial agonists and antagonists of the gaba receptors
02/03/2000WO1999063929A3 Multibinding inhibitors of microsomal triglyceride transferase protein
02/03/2000WO1999063928A3 Pharmaceutical product for hemophilia and asthmatic bronchitis treatment
02/03/2000WO1999061444A3 Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
02/03/2000WO1999058504A9 Novel 1,2,5-trisubstituted 1,2-dihydro-indazol-3-ones with anti-asthmatic, anti-allergic, anti-inflammatory, immuno-modulating and neuro-protective effect, method for the production and use thereof as a medicament
02/03/2000WO1999054459A8 Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
02/03/2000WO1999054349A3 Dermatophagoides nucleic acid molecules, proteins and uses thereof
02/03/2000WO1999050251A3 Cyclin dependent kinase inhibitors
02/03/2000WO1999034786A3 Lipase inhibiting polymers
02/03/2000WO1998055483A9 PYRROLO[2,1,5-cd]INDOLIZINE DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES
02/03/2000WO1998050365A9 Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents
02/03/2000DE19837116C1 Use of paracetamol as an appetite depressant to reduce body weight
02/03/2000DE19834816A1 Verwendung von Ectoin oder Ectoin-Derivaten in kosmetischen Formulierungen Use of ectoine or ectoine derivatives in cosmetic formulations
02/03/2000DE19834813A1 Use of glycerin and/or glycol esters of aliphatic 20-40C fatty acids, e.g., glyceryl behenate, to strengthen the barrier function of skin, e.g., to protect against skin aging
02/03/2000DE19834751A1 Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel Disubstituted bicyclic heterocycles, their preparation and their use as medicaments
02/03/2000DE19834714A1 Neue 2,3,3a,4,9,9a-Hexahydro-8-hydroxy-1H-ben[f]indole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel New 2,3,3a, 4,9,9a-hexahydro-8-hydroxy-1H-ben [f] indoles, to processes for their preparation and their use as medicaments
02/03/2000DE19834713A1 Neue Phenylethylaminderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel New phenylethylamine derivatives, processes for their preparation and their use as medicaments
02/03/2000DE19834604A1 Use of 1-(5-oxohexyl)-3-methyl-7-n-propylxanthine and 1-(5-hydroxyhexyl)-3-methyl-7-n-propylxanthine as phosphodiesterase V inhibitors to prepare medicaments for treating erectile dysfunction
02/03/2000DE19834507A1 Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil Pharmaceutical, water-soluble tablet formulation for use of sildenafil
02/03/2000DE19834506A1 Transmucosales therapeutisches System zur Anwendung von Sildenafil Transmucosal therapeutic system for the administration of sildenafil
02/03/2000DE19834505A1 Transdermal therapeutic system useful for treating male sexual impotence contains sildenafil
02/03/2000DE19834047A1 Substituierte Pyrazolderivate Substituted pyrazole derivatives
02/03/2000DE19834045A1 (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin (4-amino-5-ethylpyrimidine-2-yl) -1- (2-fluorobenzyl) -1H-pyrazolo [3,4-b] pyridine
02/03/2000DE19834044A1 Neue substituierte Pyrazolderivate New substituted pyrazole derivatives
02/03/2000DE19832784A1 Continuous production of fatty acid esters from a biological source by contact with an inert catalyst
02/03/2000CA2338741A1 Il-8 receptor antagonists
02/03/2000CA2338397A1 Methods for purifying nucleic acids
02/03/2000CA2338329A1 The use of cd4-binding small molecules to inhibit hiv infection
02/03/2000CA2338328A1 Small molecule inhibitors of bcl-2 proteins
02/03/2000CA2338310A1 Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
02/03/2000CA2338305A1 Imidazole compounds
02/03/2000CA2338279A1 Imidazoline receptor binding compounds
02/03/2000CA2338222A1 Benzoquinolizidine and benzoindolizidine derivatives and therapeutic uses thereof
02/03/2000CA2338216A1 Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
02/03/2000CA2338211A1 Use of glucose uptake enhancer for reducing apoptosis
02/03/2000CA2338209A1 Biphenyl derivatives
02/03/2000CA2338198A1 N-benzocycloalkyl-amide derivatives and their use as medicaments
02/03/2000CA2338147A1 Substituted benzimidazole antiviral agents
02/03/2000CA2338044A1 Phthalazine derivatives phosphodiesterase 4 inhibitors
02/03/2000CA2337954A1 Phthalazine derivatives as phosphodiesterase 4 inhibitors
02/03/2000CA2337945A1 .alpha.-amino acid phenyl ester derivatives
02/03/2000CA2337941A1 N,n-substituted cyclic amine compounds
02/03/2000CA2337756A1 Libraries of polyhydroxamates and their analogs
02/03/2000CA2337413A1 Substituted phenylamidines,pharmaceutical compositions containing these compounds and processes for preparing them
02/03/2000CA2337399A1 Ophthalmic compositions for treating ocular hypertension
02/03/2000CA2337349A1 Ophthalmic compositions for treating ocular hypertension
02/03/2000CA2337247A1 Isquinolines as urokinase inhibitors
02/03/2000CA2336595A1 Use of prohibitin rna in treatment of cancer
02/03/2000CA2335646A1 Genes of the dead box protein family, their expression products and use
02/03/2000CA2335620A1 Solid preparation containing sparingly soluble nsaids
02/03/2000CA2335062A1 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
02/02/2000EP0976776A1 Hypertonic aqueous dispersions of unfractioned collagen, a method and a device for the preparation of said dispersions
02/02/2000EP0976754A1 Remedies/preventives for respiratory diseases
02/02/2000EP0976752A1 C-2 S/O- and S/N-Formaldehyde acetal derivatives of carbapenem antibiotics
02/02/2000EP0976749A1 Process for preparing quinolone and naphthyridone carboxylic acids
02/02/2000EP0976748A1 Pyrrolidine derivatives having phospholipase a2 inhibitory activity
02/02/2000EP0976747A2 Use of 5HT-1F receptor antagonists for treating anxiety disorders
02/02/2000EP0976744A1 Amide, carbamate, and urea derivatives having glutamate receptor function potentiating activity
02/02/2000EP0976742A1 A synthesis of furan sulfonamide compounds useful in the synthesis of IL-1 inhibitors
02/02/2000EP0976734A2 Selective inhibitors of viral or bacterial neuraminidase
02/02/2000EP0976732A1 1,4-substituted cyclic amine derivatives
02/02/2000EP0976408A1 Cation exchange resin preparation containing gelling agent
02/02/2000EP0976407A1 Antiseptic composition
02/02/2000EP0976406A1 Transdermal composition containing glibenclamide and benzyl alcohol
02/02/2000EP0976404A2 A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
02/02/2000EP0976398A2 Use of 3,4-diphenyl chroman derivatives in the manufacture of a medicament for lowering serum cholesterol levels and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
02/02/2000EP0976395A1 Tablet for extended release of a drug in the stomach
02/02/2000EP0976381A1 Dermatologic preparation
02/02/2000EP0975774A2 Bacterial plasmids
02/02/2000EP0975766A1 Methods and compositions for synthesis of long chain polyunsaturated fatty acids
02/02/2000EP0975754A1 Osteoprotegerin binding proteins and receptors
02/02/2000EP0975750A2 Modified retinoblastoma tumor suppressor proteins
02/02/2000EP0975739A1 Stimulation, culture and preservation of pancreatic and other cells
02/02/2000EP0975680A1 Interactive system for substance presentation and elimination
02/02/2000EP0975668A1 MODIFIED TNF$g(a) MOLECULES, DNA ENCODING SUCH MODIFIED TNF$g(a) MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNF$g(a) MOLECULES AND DNA
02/02/2000EP0975654A1 Composition and method for treatment of cmv infections
02/02/2000EP0975651A1 Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease
02/02/2000EP0975650A1 Oligomers which inhibit expression of collagen genes
02/02/2000EP0975649A1 Rnase l activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies